Osteoporosis treatment with anti-IL-11 antibody
US6998123B1 · kind B1 · utility
Inventors
Key dates
| Filing date | Jan 27, 2000 |
| Grant date | Feb 14, 2006 |
| Priority date | — |
| Expiry date | Jan 27, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is disclosed a process of treating or alleviating the symptoms of pathological conditions in which bone density is decreased, which comprises inhibiting, in a mammalian patient suffering from such a condition, the formation in vivo of a tertiary complex of IL-11, its cell surface membrane receptor and the cell surface glycoprotein gp130. Examples of such substances are recombinant soluble IL-11 receptor mutants modified, as compared with native IL-11 receptor, at their gp130 binding site, and peptides which can interact with IL-11. The process of the invention not only inhibits bone resorption and hence bone loss, but also increases the process of bone formation to increase bone density.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.